University of Oxford explores antiparasitic drug ivermectin as a COVID-19 treatment | Reuters

2021-11-24 10:01:21 By : Ms. Rachel Zhong

On April 28, 2020, in Paris, France, as the coronavirus disease (COVID-19) continues to spread, a box of ivermectin drugs manufactured by Biogaran appeared on the counter of a pharmacy. REUTERS/Benoit Tessier

Reuters, June 23-The University of Oxford said on Wednesday that it is testing the antiparasitic drug ivermectin as a possible treatment for COVID-19, a study supported by the British government to help non-hospital environments recover Part.

The university stated that ivermectin caused a reduction in viral replication in laboratory studies, and added that a small pilot showed that early administration of the drug can reduce the viral load and duration of symptoms in some mild COVID-19 patients. read more

A study in the United Kingdom called PRINCIPLE in January showed that the antibiotics azithromycin and doxycycline are usually ineffective against early COVID-19. read more

Although the World Health Organization and European and American regulatory agencies recommend against using ivermectin in COVID-19 patients, it is being used to treat the disease in some countries, including India. read more

"By adding ivermectin to a large-scale trial like PRINCIPLE, we hope to generate strong evidence to determine the effectiveness of this treatment against COVID-19 and whether there are benefits or disadvantages to its use," the study's combination The lead researcher on trial said Chris Butler.

The university added that people who have severe liver disease, are taking the blood-thinning drug warfarin, or are receiving other treatments that are known to interact with ivermectin will be excluded from the trial.

The university said that ivermectin is the seventh treatment to be studied in the trial and is currently being evaluated together with the antiviral drug fapilavir.

Our standard: Thomson Reuters Trust Principles.

Subscribe to our daily featured newsletter to receive the latest exclusive Reuters reports sent to your inbox.

Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people around the world every day. Reuters provides business, financial, domestic and international news directly to consumers through desktop terminals, world media organizations, industry events and directly.

Rely on authoritative content, lawyer editing expertise, and industry-defining technology to build the most powerful argument.

The most comprehensive solution to manage all complex and expanding tax and compliance needs.

The industry leader in providing online information for tax, accounting and financial professionals.

Access unparalleled financial data, news, and content with a highly customized workflow experience on desktop, web, and mobile devices.

Browse an unparalleled combination of real-time and historical market data and insights from global resources and experts.

Screen high-risk individuals and entities on a global scale to help discover hidden risks in business relationships and interpersonal relationships.

All quotes are delayed by at least 15 minutes. Please see the complete list of exchanges and delays here.